Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00640003 · ClinicalTrials.gov registry record · Early Phase 1
Baclofen Treatment of Ataxia Telangiectasia
A Early Phase 1 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
NCT00640003: Completed Early Phase 1 study, sponsored by Johns Hopkins University.
NCT00640003 is a Early Phase 1 study that has completed, run by Johns Hopkins University. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00640003, a Early Phase 1 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This research is being done to find out if Baclofen, a medicine that is often used for the treatment of abnormal stiffness, might also be useful to treat some of the neurologic problems caused by ataxia telangiectasia (A-T). The investigators also want to find out if there are better ways to measure the problems of ataxia and abnormal eye movement for future studies of medication in ataxia telangiectasia.
Interventions
- DRUG Placebo
- DRUG Baclofen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2007-04 |
| Est. Completion | 2011-02 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00640003
The ClinicalTrials.gov registry entry for NCT00640003 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00640003 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00640003 about?
NCT00640003 is a clinical study titled "Baclofen Treatment of Ataxia Telangiectasia". This research is being done to find out if Baclofen, a medicine that is often used for the treatment of abnormal stiffness, might also be useful to treat some of the neurologic problems caused by ataxia telangiectasia (A-T). The investigators also want to find out if there are better ways to measure...
What is the current status of trial NCT00640003?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2007-04. Estimated completion is 2011-02.
What interventions are being tested in trial NCT00640003?
The interventions under investigation include: Placebo (DRUG), Baclofen (DRUG).
Who is sponsoring clinical trial NCT00640003?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.